T otal knee arthroplasty (TKA) is one of the most common elective surgical procedures, with over 450,000 cases performed annually in the United States alone. 1 The number of TKA procedures has doubled in each of the past 2 decades and is expected to continue to increase as the population ages. [1] [2] [3] These surgeries are among the most expensive procedures, with hospital, implant, and physician charges averaging nearly $40,000 per case and totaling $15 to $18 billion annually in the United States. 2, 3 Despite these high costs, TKA is one of the most cost-effective interventions relative to other medical treatments because TKA provides substantial improvements in quality of life because of reduced pain and increased mobility. 4, 5 How society will underwrite the associated costs of high-value interventions like TKA is unknown. 3, 6, 7 Consequently, health care providers have attempted to contain costs through various interventions such as competitive bidding for implants, 7, 8 decreasing medication costs, [8] [9] [10] clinical pathways, 11 and shortening the period of hospitalization. 12 Using a hospital-based epidural or continuous femoral nerve block (CFNB) for 48 to 72 hours, anesthesiologists have reported shortened institutionalization from 50 to 40 days (France), 21 to 17 days (Belgium), and 5 to 4 days (United States) compared with using only intravenous opioids. [13] [14] [15] However, hospitalization length of stay in the United States has changed little over the past decade, 1 persistently averaging 4 days, at least in part because of the need for potent analgesia after TKA. 16 Unlike intravenous opioids or epidural infusion of local anesthetic with or without opioids, perineural local anesthetic infusion does not require hospitalization. 17 In a recent prospective longitudinal cohort study, conventional TKA (nonminimally invasive) was performed as an overnightstay procedure in 9 of 10 selected patients by using small, portable infusion pumps that allowed discharge directly home with the CFNB in situ for over 4 postoperative days (PODs). 18 All of these patients reported analgesia equal or superior to patients with hospital-based CFNB. [13] [14] [15] 19 without any associated complications. Providing ambulatory CFNB was primarily an attempt to enable earlier discharge in motivated patients who desired convalescence in the comfort of their own homes. However, this study did not include a control group and any reduction in length of stay remains speculative. Moreover, an additional possible indirect benefit of this intervention may have been a decrease in the associated costs of hospitalization.
Therefore, the goal of this retrospective, casecontrol study was to examine the relationship between providing a CFNB on an ambulatory versus hospital-only basis and hospitalization costs after conventional TKA.
Methods
After institutional review board (University of Florida, Gainesville, FL) approval, we examined the medical records for patients who underwent TKA at 1 institution (Shands Hospital at the University of Florida, Gainesville, FL) with a single orthopedic surgeon during an 18-month period beginning January 2004 (Fig 1) . Patients who had participated in a pilot study or a randomized clinical trial (RCT) were excluded. Subjects were retained for further evaluation if they had undergone unilateral, primary, tricompartment, cemented TKA for osteoarthritis under a general anesthetic. Furthermore, the postoperative analgesic regimen required for study retention included a CFNB with ropivacaine, 0.2% (basal infusion Ն5 mL/ h), and 10 mg of controlled-release oxycodone administered twice each day.
Study Group Assignment
"Cases" were defined as patients who were discharged home with their CFNB, all of whom had participated in a previously published institutional review board-approved prospective longitudinal cohort study. 18 Of note, these subjects were a unique subset of patients in that they were all under 70 years of age, had no known cardiac disease or risk factors for deep vein thrombosis, and were interested in returning home the day after a TKA. 18 All other remaining patients who had received a hospital-based CFNB were designated as "controls." Care and resource use for each of the treatment groups was similar except for the earlier discharge in the CFNB group (Table 1) . For example, physical therapy for CFNB patients was delivered at home by the same department as the inpatients so costs for physical therapy were captured under hospital costs/charges for both groups.
Data were transferred by keypunch entry into a computerized database (Office Excel 2003; Microsoft Corporation, Bellevue, WA). Each case was matched with 1 control for the following variables: age (Ϯ5 years), gender, body mass index (Ϯ5 kg/ m 2 ), and American Society of Anesthesiologists physical status. Investigators were blinded to the duration of both hospitalization and CFNB for the control group during the matching process. 
Outcome Measures
The primary endpoint was the hospitalization cost. Included in this value were costs for the preoperative clinic visit, day of surgery, postoperative hospital course including room and board, home nursing visit, and physical and occupational therapy during the first postoperative week (for both inand outpatient sessions). The cost of the knee implant itself and physician professional fees were excluded for the primary endpoint. Secondary endpoints included hospitalization charges (including room and board), room/board costs and charges (separate from other costs and charges), implant charges, and physician professional fees. Additional secondary endpoints included the surgical, CFNB, and hospitalization durations. Financial data were extracted by using the hospital's internally developed microcosting database. Because of the short time span of charges that were reviewed (18 months), no adjustments were made for inflation.
Statistical Analysis
Sample-size calculations were derived based on the primary hypothesis that providing ambulatory CFNB is associated with a decrease in hospitalization costs compared with providing CFNB solely during hospitalization. Therefore, the costs of hospitalization (excluding physician professional fees and implant cost) were used to estimate a probable sample size. Because the cases were comprised of only 10 patients who were provided ambulatory CFNB, the only variable that could be manipulated to power the study was the number of control subjects assigned to each ambulatory CFNB subject. Based on published data, 1,3,12,20 mean costs of hospitalization for patients with hospital-only CFNB (controls) was anticipated to be $10,000 in US dollars. A $1,500 (15%) difference in costs between groups was considered to be economically relevant. Assuming a standard deviation in both groups of $1,000, a 2-sided type I error protection of 0.05, and a power of 0.80, only 1 control subject per case subject was required to show an economically significant difference between study groups for the primary endpoint (SigmaStat 3.1; SPSS, Inc., Chicago, IL).
Normality of distribution was determined using the Kolmogorov-Smirnov test (NCSS Statistical Software, Kaysville, UT). Possible differences between groups were analyzed using a t test or Wilcoxon Rank-Sum test for parametric and nonparametric data, respectively. Categorical data were analyzed using the chi-square test with Yates continuity correction. P Ͻ .05 was considered significant.
Results
Ten cases were successfully matched with an equal number of controls (Fig 1 and Table 2 ).
Primary Endpoint
The total median (range) hospitalization costs for ambulatory CFNB cases was $5,292 ($4,326-$7,929) compared with $7,974 ($6,931-$9,979) for control patients with a CFNB only during hospitalization (difference ϭ $2,682, 34% lower than the cost of controls; P Ͻ .001, Fig 2) .
Secondary Endpoints
Of the 10 cases with ambulatory CFNB, 9 patients were discharged home on POD 1, and 1 was discharged home in the morning of POD 4 because of a bowel obstruction that resolved on POD 3. 18 All cases retained their CFNB using portable infusion pumps on discharge that enabled perineural ropivacaine infusion at home until POD 4. In contrast, control subjects had their CFNB discontinued before discharge, with an infusion duration of 2 days for 7 patients and 3 days for 3 patients. Of these 10 control subjects, discharge occurred on POD 3 for 3 patients, POD 4 for 6 patients, and POD 5 for 1 patient. The total charges for hospitalization, the implant, and professional fees were $33,646 ($31,816-$38,468) for cases compared with $39,100 ($36,096-$44,098) for controls (difference ϭ $5,454, 14% lower than the cost of controls, P Ͻ .001, Fig 2) . Additional secondary endpoints are presented in Figure 2 and Table 3 .
Discussion
This retrospective, case-control study provides evidence that after conventional (nonminimally in- 
NOTE. Values are reported as mean Ϯ standard deviation. There were no statistically significant differences between treatment groups.
Abbreviations: CFNB, continuous femoral nerve block; ASA, American Society of Anesthesiologists; F, female; M, male.
vasive) TKA allowing hospital discharge with an ambulatory CFNB is associated with a 34% ($2,682 per patient) decrease in hospitalization costs compared with inpatient-only CFNB. Nearly two thirds of the savings resulted from lower room and board costs, as might be expected with all but one of the case subjects hospitalized just 1 night compared with 3 to 5 nights for control subjects. However, The costs and charges related to total knee replacement surgery for patients with an ambulatory continuous femoral nerve block (CFNB, "cases") and hospital-only CFNB ("controls"). The horizontal lines demarcate the group means. Of the patients in the ambulatory CFNB group, the highest data point in every panel (except professional fees) denotes the 1 subject who required 4 days of hospitalization as a result of a bowel obstruction.
this leaves over 38% of the cost savings resulting from additional sources.
When charges, as opposed to costs, are compared, the per-patient savings increases to $6,083 (29%). This finding may be relevant to insurers with contracts to pay discounted fee-for-service rates. When the total TKA-related charges are calculated with the addition of the implant and physician professional fees, the per-patient savings was $5,454 (14%). Considering over 450,000 TKA procedures are performed annually in the United States alone, the potential savings to society may be significant, as long as increased complication or caretaker costs do not appreciably increase total costs. This study helps quantify the potential for anesthesiologists to contribute to TKA cost containment by providing ambulatory CFNB. A reliable projection of possible annual savings requires information not currently available from either this study or the published literature.
Cost-Minimization Analysis
Convened by the United States Public Health Service, the Panel of Cost Effectiveness in Health and Medicine published a set of standards to facilitate the comparability of cost-benefit analyses. 21 The current study follows these methodological guidelines. 21 In cost-effectiveness analysis, as defined by the panel, the "added costs and health outcomes associated with a program are used to calculate the incremental cost-effectiveness ratio relative to some comparator." 21 However, the retrospective nature of the current study did not allow for comparison of similarly collected health-outcome data. Therefore, the present study is a type of cost-effectiveness analysis labeled cost-minimization analysis, in which the "effectiveness of the intervention and the comparator are presumed to be equal." 21 Although preliminary evidence suggests that providing CFNB at home on POD 1 to 4 results in equal or superior outcomes compared with hospital-only CFNB, 13, 14, 18, 19, 22 substantiation of this assertion requires a large-sample, multiyear RCT. Although there were no complications related to early discharge in the small cohort on which the current study is based, a hospital readmission rate of only 10% would probably negate any cost savings.
Related to these issues, the panel proposed that, "although the effectiveness of alternative programs is rarely exactly equal, this assumption may be a reasonable approximation in some cases [of costminimization analysis]." 23 And, although the patients of the current study did not receive lowmolecular-weight heparin, given the recent report of clinically relevant hematoma after femoral catheter placement for TKA associated with low-molecular-weight heparin administration, great caution is warranted by all practitioners discharging patients home with a catheter in situ. 23 As recommended by the panel, the primary outcome measure for this analysis involved costs, as opposed to charges. 21 Analyzing costs instead of charges is preferred because market distortion or imperfection may significantly influence the relationship between prices (charges) and resource requirements (costs). 21, 24 Typically, hospitals increase charges by a certain percentage each year. Hospitals tend not to individually adjust the pricing for each charge code to bring the charge value in line with the item's current cost. Thus, the relationship between charge values and items' actual costs can be inconsistent. However, secondary outcome measures are provided to allow comparisons from additional perspectives, which may provide useful information to various specific interests and audiences.
A distinctive feature of cost data in health care is its asymmetrical distribution (skewed to the right) and large variance. Causes of skewed (e.g., rightsided tail) data include that the severe cases require substantially more resources. The 3 measures of central tendency or "average" value of the distribution are mode, median, and mean. The high-cost patients will influence some measures of central tendency (the mean cost will be "increased" because of the right tail cases) but not others (medians). For these reasons, we have presented data as median (ranges). However, when information about the costs of alternative treatments is to be used to guide health care policy decision making, it is the total budget needed to treat patients with the disease that is relevant. An estimate of this total cost is obtained from data in a trial by multiplying the arithmetic mean (average) cost in a particular treatment group by the total number of patients to be treated. It is therefore the arithmetic mean that is the informative measure for cost data in pragmatic clinical trials, and we have therefore provided the mean (Ϯ standard deviation) data in Table 3 .
Cost Shifting
Similarly, some of the costs of care on POD 2 to 5 may be transferred from hospitals and orthopedic surgeons to anesthesiologists and family members. In the current study, there was minimal change in anesthesiologists' time commitment (costs) by providing ambulatory CFNB because they provide analgesia regardless of the patients' location or reimbursement (charges) because CFNB is billed as a global fee regardless of infusion duration. However, patients returning home with an ambulatory CFNB required a caretaker for the duration of the infusion. 18 For the cases, patient caretakers were comprised exclusively of retired spouses, and therefore calculations did not include forgone wages. But information regarding potential caretakers for control subjects was unavailable because of the retrospective nature of the study design, and it is therefore impossible to calculate any opportunity cost for these individuals. Regardless of these missing data, the panel noted that, "if an intervention requires . . . time spent away from other activities (including leisure), then there has been a change in the way resources are used, even if there is no monetary transaction. In such cases, there are opportunities forgone, and a 'cost' results in the form of the loss of the benefits that would come from the alternative use of time." 21 Such a cost calculation is extremely complex and highly population dependent 25 and was therefore not attempted by the authors. It is thus an acknowledged weakness of the present study. Future cost-effectiveness investigations into ambulatory CFNB should include both the costs and effects of requiring patient caretakers to remain at home for various populations.
Other factors besides caretaker opportunity costs were beyond the scope of this analysis, yet would be expected to influence the financial scenario of implementing ambulatory CFNB. For example, although the median per-patient total charges were $5,454 (14%) less in the ambulatory CFNB group and therefore a fall in the per-patient average hospital revenue might be expected, total hospital revenue might actually be increased if the resulting empty hospital beds allowed performance of additional TKA procedures. Given this scenario, ambulatory CFNB may not reduce financial costs from a societal perspective but rather enable an increased number of procedures and thereby increase quality of life by decreasing the often long wait for joint replacement. 26, 27 In addition, charges must not be confused with collections: although ambulatory CFNB was associated with a median per-patient decrease in total charges of $5,454 (14%), actual collections remained unchanged. This may be explained by the hospital having prenegotiated TKA reimbursement with various insurers so that payment is independent of hospitalization duration. Therefore, because hospital costs decreased by a median of $2,682 (34%) per patient, the hospital may have actually increased its per-patient profit margin and simultaneously increased its ward capacity having staffed beds now available for other patients.
Study Limitations
This investigation involved only 1 orthopedic surgeon operating from a single university hospital. Evidence for internal validity may be found in the 1 subject who was provided ambulatory CFNB but remained hospitalized until POD 4 because of a bowel obstruction; the costs and charges of her care were similar to those of control subjects (Fig 2) . However, the external validity remains unknown and undoubtedly would have been improved by a larger sample of institutions and surgeons. In addi-tion, this study had a limited number of patients. We are currently designing larger studies now that investigation feasibility is established. 18 Of note, the average per-patient total charge for the control group is similar to the national mean, suggesting that the hospital of this study is a relatively good representation of other institutions in the United States. 2, 3 A significant limitation of the present study is its retrospective, nonrandomized design, which introduces inherent biases shared by all case-control studies. We controlled for 11 confounding variables but certainly do not imply definitive conclusions with these data. One potential source of bias is the study protocol used for the 10 patients provided ambulatory CFNB. 18 However, this protocol was designed specifically to reflect the 1 surgeon's standard clinical pathway that was also used for the control patients (including specific discharge criteria). Differences between the protocol used for the cases and controls were minimal but may have had an effect on the outcome measures (Table 1) . Of note, we could not account for the postdischarge oral analgesic and thromboprophylactic prescription costs/charges because these were financially covered by patients' insurance companies and not included in the hospital microcosting database. Yet, prescriptions for patients of both groups were identical so this omission should have no effect on between-group comparisons. In addition, we cannot exclude a possible "healthy volunteer effect" in which patients who choose to participate in prospective research have better outcomes than other patients. 28 
Analysis Model
The time horizon for this study began with the preoperative visit and included the day of surgery and first postoperative week. However, if ambulatory CFNB increased or decreased subsequent care requirements, those costs and charges should be included in any future cost-consequence analysis. Follow-up analysis of the ambulatory CFNB group does not suggest supplemental care was necessary, but a large RCT is required for confirmation.
In summary, the results of this retrospective, case-control investigation suggest that providing ambulatory CFNB after TKA is associated with a decrease in hospitalization costs and charges. However, the current study has significant inherent limitations based on the study design. Additional research is required to confirm these findings with a prospective RCT and measure the long-term costs and benefits of this relatively new intervention. Although these results help identify and quantify the potential for anesthesiologists to contribute to TKA cost containment, it is not the authors' intention to suggest that financial considerations dictate the use of ambulatory CFNB to enable earlier discharge after TKA. Rather, ambulatory CFNB may be provided for multiple other reasons, all of which require additional confirmatory study, with a decrease in related costs being an indirect benefit. 18 It is well established that "changing technology in medicine results in increased spending and accounts for one half to two thirds of the increase in health care spending in excess of general inflation [in the United States]." 6 It is therefore notable that ambulatory CFNB may be a rare instance of a new technology holding the promise of both improving outcomes and reducing societal costs.
